key: cord-0891516-h4sbz3md
authors: Muecksch, Frauke; Wang, Zijun; Cho, Alice; Gaebler, Christian; Tanfous, Tarek Ben; DaSilva, Justin; Bednarski, Eva; Ramos, Victor; Zong, Shuai; Johnson, Brianna; Raspe, Raphael; Schaefer-Babajew, Dennis; Shimeliovich, Irina; Daga, Mridushi; Yao, Kai-Hui; Schmidt, Fabian; Millard, Katrina G.; Turroja, Martina; Jankovic, Mila; Oliveria, Thiago Y.; Gazumyan, Anna; Caskey, Marina; Hatziioannou, Theodora; Bieniasz, Paul D.; Nussenzweig, Michel C.
title: Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose
date: 2022-02-15
journal: bioRxiv
DOI: 10.1101/2022.02.14.480394
sha: 35fe940dce0cb8e98f68b4b0948701ca9cff51c1
doc_id: 891516
cord_uid: h4sbz3md

The omicron variant of SARS-CoV-2 infected very large numbers of SARS-CoV-2 vaccinated and convalescent individuals1–3. The penetrance of this variant in the antigen experienced human population can be explained in part by the relatively low levels of plasma neutralizing activity against Omicron in people who were infected or vaccinated with the original Wuhan-Hu-1 strain4–7. The 3rd mRNA vaccine dose produces an initial increase in circulating anti-Omicron neutralizing antibodies, but titers remain 10-20-fold lower than against Wuhan-Hu-1 and are, in many cases, insufficient to prevent infection7. Despite the reduced protection from infection, individuals that received 3 doses of an mRNA vaccine were highly protected from the more serious consequences of infection8. Here we examine the memory B cell repertoire in a longitudinal cohort of individuals receiving 3 mRNA vaccine doses9,10. We find that the 3rd dose is accompanied by an increase in, and evolution of, anti-receptor binding domain specific memory B cells. The increase is due to expansion of memory B cell clones that were present after the 2nd vaccine dose as well as the emergence of new clones. The antibodies encoded by these cells showed significantly increased potency and breadth when compared to antibodies obtained after the 2nd vaccine dose. Notably, the increase in potency was especially evident among newly developing clones of memory cells that differed from the persisting clones in targeting more conserved regions of the RBD. Overall, more than 50% of the analyzed neutralizing antibodies in the memory compartment obtained from individuals receiving a 3rd mRNA vaccine dose neutralized Omicron. Thus, individuals receiving 3 doses of an mRNA vaccine encoding Wuhan-Hu-1, have a diverse memory B cell repertoire that can respond rapidly and produce antibodies capable of clearing even diversified variants such as Omicron. These data help explain why a 3rd dose of an mRNA vaccine that was not specifically designed to protect against variants is effective against variant-induced serious disease.

the 3 rd dose, from IC50 290 ng/ml to 111 ng/ml was highly significant (p=0.0023, Fig. 3a and 142 Supplementary Table 3) . Notably, the potency of antibodies isolated after the 3 rd dose, 143 approximately 10 months (293 (223-448) days) after the prime-dose, was indistinguishable from 144 antibodies isolated from convalescent vaccinated individuals 12 months after infection (p=0.69, 145 Fig. 3a) 17-19 . The improved neutralizing activity was most evident among unique clones with a 146 dramatic change in IC50 from 323 to 67ng/ml, p=0.034 ( Fig. 3b and Supplementary Table 3) . 147

Persisting clones also showed improved neutralizing activity after the 3 rd dose (p=0.043, Fig. 3b ) 148 and a trend to improved neutralizing activity was evident among single antibodies but this did not 149 reach statistical significance (Fig. 3b , Extended data Fig. 5d and Supplementary Table 3 and 4) . In 150 all cases, the relative potency of the antibodies isolated 1 month after the 3 rd dose was similar to 151 the antibodies isolated from convalescent vaccinated individuals 12 months after infection ( The majority of the anti-RBD neutralizing antibodies obtained from vaccinated individuals after 160 the 2 nd vaccine dose belong to class 1 and 2 that target a region overlapping with the ACE2 binding 161 site 20,21 (Fig. 4a) . These antibodies are generally more potent than class 3 and 4 antibodies that 162 target the more conserved base of the RBD and do not directly interfere with ACE2 binding ( 17 , 163 Fig. 4a and Extended data Fig. 6 ). Whereas class 1 and 2 antibodies that develop early are 164 susceptible to mutations in and around the ACE2 binding site found in many of the variants of 165 concern, evolved versions of the same antibodies can be resistant 17, 22 . Based on structural 166 information and sequence conservation among betacoronaviruses, antibodies that span class 3 or 167 4 and either class 1 or 2 could be broadly active ( Fig. 4b and Extended data Fig. 6 ). 168 169 To examine epitopes targeted by RBD-binding antibodies after the 3 rd vaccine dose, we performed 170 BLI experiments in which a preformed antibody-RBD complex was exposed to a second antibody 171 targeting one of four classes of structurally defined epitopes (C105 as Class 1; C144 as Class 2, C135 as Class 3 and C118 as Class 1/4 18,20 ) (Fig. 4a) . 168 random RBD binding antibodies were 173 tested among which 20, 29, and 36 neutralized with IC50s lower than 1000 ng/ml from 1.3 and 5-174 months after the 2 nd and 1 month after the 3 rd vaccine dose respectively. As might be expected the 175 largest group of RBD binding antibodies obtained after the 2 nd vaccine dose belonged to class 1/2 176 (Fig. 4c) . Although the overall distribution of antibody classes that bind to RBD did not change 177 significantly between 1.3 and 5-months after the 2 nd dose, the relative representation of class 1 and 178 2 antibodies decreased (Fig. 4c) . This trend continued after the 3 rd vaccine dose with increased 179 representation of RBD binding antibodies in class 1/4 and 3 resulting in a significant difference in 180 the epitope distribution among RBD-binding antibodies between the early time points after the 2 nd 181 and the 3 rd dose (p=0.005, Fig. 4c ). As expected, these differences can be accounted for primarily 182 by the emergence of new clones and singlets after the 3 rd vaccine dose (Fig. 4d) . Similar results 183 were found when considering the neutralizing antibodies with initial dominance of class 1/2 and 184 increasing representation of class 1/4 and 3 over time (Fig. 4e) . 185

The neutralizing breadth of antibodies elicited by infection increased significantly after 5 months 187 17,19,22 . There was also a trend to increased breadth that did not reach statistical significance 5 188 months after the 2 nd dose of an mRNA vaccine 10 . To determine whether neutralizing antibodies in 189 clones that persisted from 5 months after the 2 nd to 1 month after the 3 rd dose develop increased 190 breadth, we compared 18 antibody pairs. Neutralizing activity was measured against a panel of 191 SARS-CoV-2 pseudoviruses harboring RBD amino acid substitutions representative of CoV-2 variants including Delta and Omicron (Fig. 5a) . The clonal pairs were dominated by 193 antibodies belonging to class 1/2, 2/3 and 3, as determined by BLI (Fig 5a) . 15 out of 18 antibody 194 pairs neutralized the pseudovirus carrying the Delta RBD-amino acid substitutions at low antibody 195 concentrations at both time points, with IC50 values ranging from 1-154 ng/ml (Fig. 5a) . While the 196 Omicron pseudovirus showed the highest degree of neutralization resistance, 11 out of 18 197 antibodies isolated 1 month after the 3 rd dose neutralized this virus, 9 of those at IC50s below 120 198 ng/ml (Fig. 5a) . Most antibody pairs isolated before and after the 3 rd vaccine dose showed 199 exceptionally broad neutralization and there was little change in antibody breadth within the 200 analyzed pairs (Fig. 5a) . 201

We extended the analysis to compare the activity of antibodies present in memory cells found 1.3 203 months after the 2 nd and unique to 1 month after the 3 rd vaccine dose. The antibodies were tested 204 against viruses pseudotyped with spike proteins containing the RBD of Wuhan-Hu-1, Delta and 205 Omicron (Fig. 5b) . We found that the proportion of Omicron-neutralizing antibodies increased 206 from 15% after the 2 nd dose to 50% among the unique antibodies found after the 3 rd dose (p=0.035, 207

Fisher's exact test. Fig 5b) . Among all antibodies evaluated, the increase in breadth between the 208 2 nd and 3 rd vaccine dose was reflected by an increase in potency from 689 to 124 ng/ml IC50 against 209

Omicron (p=0.0004, Fig 5c) . Similar results were seen for Delta neutralization (Fig. 5c) proportional to the number of clonally related sequences. The most conserved residues calculated by the ConSurf Database were shown in yellow (related 316

to Extended data Fig. 6) . b, RBD in a was enlarged. ACE2 epitope of Omicron variant was 317 indicated by blue dashed lines, and Omicron mutations were labeled. c-e, Results of epitope 318 mapping performed by competition BLI. Pie charts show the distribution of the antibody classes 319 among all RBD binding antibodies (c), RBD binding antibodies from persisting clones or unique 320 clones or singlets (d), or neutralizing antibodies against Wuhan-Hu-1 (e) obtained 1.3-and 5-321 months after Vax2 9,10 , and 1 month after 3 rd vaccine dose (Vax3). Statistical significance was 322 determined using a two-tailed Chi-square test. 323 The E484K, K417N/E484K/N501Y and L452R/T478K substitution, as well as the 422 deletions/substitutions corresponding to variants of concern listed above were incorporated into a 423 spike protein that also includes the R683G substitution, which disrupts the furin cleaveage site and 

SARS-CoV-2 Infection and Hospitalization Among Adults Aged >/=18 Years, 559 by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant 560 Predominance

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA 565 vaccination

mRNA booster immunization elicits potent neutralizing serum activity 567 against the SARS-CoV-2 Omicron variant

Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-570 2 variants

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster 572 Vaccination

Neutralising antibody titres as predictors of protection against SARS-574

CoV-2 variants and the impact of boosting: a meta-analysis

Neutralizing antibody levels are highly predictive of immune protection 577 from symptomatic SARS-CoV-2 infection

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after 582 infection

Convergent antibody responses to SARS-CoV-2 in convalescent 584 individuals

Evolution of antibody immunity to SARS-CoV-2

SARS-CoV-2 neutralizing antibody structures inform therapeutic 588 strategies

Structural basis of a shared antibody response to SARS-CoV-2

Affinity maturation of SARS-CoV-2 neutralizing antibodies confers 592 potency, breadth, and resilience to viral escape mutations

Antibody Affinity Shapes the Choice between Memory and Germinal Center 595 B Cell Fates

Germinal center-dependent and -independent memory B cells produced 597 throughout the immune response

Germinal center B cells govern their own fate via antibody feedback

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody 601

Neutralizing monoclonal antibodies for treatment of COVID-19

Neutralizing Antibodies for COVID-19 Prevention and Treatment

REGN-COV2, a Neutralizing Antibody Cocktail

Subcutaneous REGEN-COV Antibody 610 Combination to Prevent Covid-19. Reply

Rapid cloning of high-affinity human monoclonal antibodies against 613 influenza virus

Effect of Bamlanivimab as Monotherapy or in Combination With 615 Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized 616 Clinical Trial

A new coronavirus associated with human respiratory disease in China. 618

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped 620 and chimeric viruses

A serological assay to detect SARS-CoV-2 seroconversion in humans

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with 624 COVID-19 Disease and Unexposed Individuals

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal 627 Common Epitopes and Recurrent Features of Antibodies

Escape from neutralizing antibodies by SARS-CoV-2 spike protein 630 variants

Enhanced SARS-CoV-2 neutralization by dimeric IgA

Change-O: a toolkit for analyzing large-scale B cell immunoglobulin 634 repertoire sequencing data

High frequency of shared clonotypes in human B cell receptor repertoires. 637

Antibody Repertoires for Exploring Antibody Diversity and Predicting Antibody 640 Prevalence

Fast, scalable generation of high-quality protein multiple sequence 642 alignments using Clustal Omega

ConSurf 2005: the projection of evolutionary conservation scores of 644 residues on protein structures

We thank all 648 members of the M.C.N. laboratory for helpful discussions, Maša Jankovic for laboratory support 649 and Kristie Gordon for technical assistance with cell-sorting experiments

R01AI78788 to T.H.. F.M. was supported by the Bulgari Women and Science

Fellowship for COVID-19 Research. C.G. was supported by the Robert S

National 654 Institutes of Health Clinical and Translational Science Award program, grant UL1 TR001866), 655 and by the Shapiro-Silverberg Fund for the Advancement of Translational Research

are Howard Hughes Medical Institute Investigators. This article is subject to HHMI's 657

Open Access to Publications policy. HHMI lab heads have previously granted a nonexclusive CC 658 BY 4.0 license to the public and a sublicensable license to HHMI in their research articles

Author Contributions

recruited participants, executed 668 clinical protocols

Corresponding authors: Correspondence should be addressed to Theodora Hatziioannou

Declaration of interests: The Rockefeller University has filed a provisional patent application in 675 connection with this work on which M.C.N. is an inventor (US patent 63/021,387). P.D.B. has 676 received remuneration from Pfizer for consulting services relating to SARS-CoV-2 vaccines

Extended Data Fig. 1: Plasma ELISA. Graph shows area under the curve (AUC) for plasma a

IgA antibody binding to SARS-CoV-2 RBD after prime 10 , 1.3 months (m) and 5 682 months (m) after the 2 nd vaccine dose (Vax2) 9,10 , and 1 month after the 3 rd (Vax3) for n=43 683 samples. Lines connect longitudinal samples. Red bars and value represent geometric mean values. 684 Statistical significance was determined by two-tailed Kruskal-Wallis test with

Extended Data Fig. 2: Flow Cytometry. a, Gating strategy for phenotyping. Gating was on 688 lymphocytes singlets that were CD19 + or CD20 + and CD3-CD8-CD16-Ova-. Anti-IgG

Representative 691 flow cytometry plots of RBD-binding memory B cells in 8 individuals after prime 10 , 1.3-and 5-692 months post-Vax2 9,10 , and 1 month after Vax3. Time point of sample collection indicated to the 693 left. Pfizer vaccinees indicated by (P) and Moderna by (M) across the top. c, Graph showing 694 frequency of RBD-specific MBCs expressing activation marker CD71 over time after vaccination 695 for n=36 samples. Red bar indicated median value. d, Graph showing the phenotype of RBD-696 specific B cells over time

IgD-CD27-) or naïve B cells (IgD+CD27+), for 698 n=18 samples. Lines connect longitudinal samples. f, Gating strategy for single-cell sorting for 699 CD20+ memory B cells for RBD-PE and RBD-AF647

Sequences used for the alignment 731 are the RBDs of WIV1

Multiple sequence alignment of RBDs was processed by Clustal 739 Omega 43

Supplementary Table 1: Individual participant characteristics

Supplementary Table 2: Sequences of anti-SARS-CoV-2 RBD IgG antibodies

Supplementary Table 3: Sequences, half-maximal effective concentrations (EC50s) and 747 inhibitory concentrations (IC50s) of cloned monoclonal antibodies

Supplementary Table 4: Binding and Neutralization activity of persisting clones

We thank all study participants who devoted time to our research, The 647

were assigned based on their V and J genes using in-house R and Perl scripts. All scripts and the 505 data used to process antibody sequences are publicly available on GitHub 506 (https://github.com/stratust/igpipeline/tree/igpipeline2_timepoint_v2). 507The frequency distributions of human V genes in anti-SARS-CoV-2 antibodies from this study 508 was compared to 131,284,220 IgH and IgL sequences generated by 41 All experiments were performed at least twice. 729